Results 121 to 130 of about 13,861 (164)

Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors. [PDF]

NPJ Precis Oncol
Jungwirth G, Paul A, Wöllner A, Warta R, Cao J, Fermi V, Jassowicz L, Dao Trong P, von Deimling A, Debus J, Krieg S, Unterberg A, Abdollahi A, Herold-Mende C.   +13 more
europepmc   +1 more source

Do ethnic differences influence the response to immunotherapy in advanced cervical cancer? [PDF]

Transl Cancer Res
Giannecchini GV, Filgueiras ABT, de Andrade DAP, de Melo AC.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Topotecan

Reactions Weekly, 2016
  +7 more sources

Clinical Pharmacokinetics of Topotecan

Clinical Pharmacokinetics, 1996
Topotecan (Hycamtin), a semisynthetic water-soluble derivative of camptothecin, is a potent inhibitor of DNA topoisomerase I in vitro and has demonstrated encouraging antitumour activity in a wide variety of tumours, including ovarian cancer and small cell lung cancer.
Herben, V.M.M., ten Bokkel Huinink, W.W., Beijnen, J.H.   +2 more
openaire   +3 more sources

Isolation and structural confirmation of N -desmethyl topotecan, a metabolite of topotecan

Cancer Chemotherapy and Pharmacology, 1997
A sensitive high-performance liquid chromatography (HPLC) method for the determination of topotecan and total levels of topotecan (lactone plus its ring-opened hydroxycarboxylate form) was developed by the authors and used in several pharmacokinetics studies. During the analysis of plasma and urine samples collected in those studies, an additional peak
Rosing, H., Herben, V.M.M., van Gortel-van Zomeren, D.M., Hop, E., Kettenes-van den Bosch, J.J., ten Bokkel Huinink, W.W., Beijnen, J.H.   +6 more
openaire   +3 more sources

Topotecan

Reactions Weekly, 2002
Ines Mader, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, Sabine M. Wassertheurer   +5 more
  +5 more sources